Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818752 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 955
- Enrollment target
- 20
- Study locations
NCT01818752: Completed Phase 3 study of Multiple Myeloma, sponsored by Amgen.
NCT01818752 is a Phase 3 study of Multiple Myeloma that has completed, run by Amgen. The registered enrollment target is 955 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01818752, a Phase 3 study of Multiple Myeloma, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 955 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).
Primary Outcome
Progression-free survival was defined as the time from randomization to the earlier of documented disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier methods. The duration of PFS was censored for participants with no baseline and/or post-baseline disease assessments, who started a new anti-cancer therapy before documentation of disease progression or death, death or disease progression after missed disease assessment of 100 consecutive days or longer, or who were a
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Prednisone
- DRUG Carfilzomib
- DRUG Bortezomib
Study Locations (20)
California
- California Cancer Associates for Research & Excellence, Inc. (cCARE) - Fresno
- Marin Cancer Care - Greenbrae
- Sutter Gould Medical Foundation - Modesto
- Innovative Clinical Research Institute - Whittier
New South Wales
- Royal Prince Alfred Hospital - Camperdown
- St. Vincent's Hospital Sydney - Darlinghurst
- Central Coast Local Health District - North Gosford
- Calvary Mater Newcastle - Waratah
South Carolina
- Saint Francis Health System - Greenville
- Spartanburg Regional Healthcare System - Spartanburg
- Santee Hematology Oncology - Sumter
New York
- Maimonides Cancer Center - Brooklyn
- Weill Cornell Medical Center - New York
Other
- Centro de educacion medica c investigacioncs clinicas "Norberto Quimo' (CEMIC) - Buenos Aires
- Sanatorio Britanico S.A. - Santa Fe
Florida
- UF Health Shands Cancer Hospital - Gainesville
Illinois
- Evanston KelIogg Cancer Center - Evanston
Montana
- Billings Clinic Cancer Center - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 955 participants |
| Start Date | 2013-07-08 |
| Est. Completion | 2016-11-04 |
| Phase | Phase 3 |
What the finished NCT01818752 record still lists
NCT01818752 is an interventional study that assigns participants to a tested intervention. The registered 955 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT01818752 names 20 study sites across 10 states, led by California, New South Wales, South Carolina.
Frequently Asked Questions
What is clinical trial NCT01818752 about?
NCT01818752 is a clinical study titled "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma". The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).
What is the current status of trial NCT01818752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 955 participants. The study started on 2013-07-08. Estimated completion is 2016-11-04.
What conditions does trial NCT01818752 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01818752?
The interventions under investigation include: Melphalan (DRUG), Prednisone (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01818752?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01818752 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Montana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01818752's enrollment target sits among peer trials
955 24th of 438 higher than 415 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI